Clik here to view.
Promega Launches OncoMate™ MSI Dx Analysis System in US
MADISON, Wis. Promega Corporation today launched its OncoMate™ MSI Dx Analysis System (OncoMate™ MSI) in vitro diagnostic (IVD) in the US, giving oncologists and pathologists a new option to screen...
View ArticleClik here to view.
Advanced Clinical Continues Global Expansion Into Asia-Pacific With New...
CHICAGO Advanced Clinical, a global clinical research services organization, is pleased to announce that the company’s global expansion into the Asia-Pacific (APAC) region continues with the opening...
View ArticleClik here to view.
ITM and Chengdu Gaotong Isotope Co. Ltd. Form Joint Venture to Expand Access...
GARCHING & MUNICH, Germany ITM AG, a leading radiopharmaceutical biotech company, today announced that it has signed a strategic long-term agreement to create a Joint Venture with Chengdu...
View ArticleClik here to view.
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
知临集团有限公司已获得美国 FDA 批准试验用新药的申请，启动用于治疗神经母细胞瘤的再利用小分子药物 SACT-1 的临床试验
纽约、伦敦和巴黎 (美国商业资讯)– 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧交易所股票代码：APM）（“知临集团”或“知临”），一家专注于包括靶向肿瘤疾病在内的新技术的临床阶段生物制药公司，宣布该集团已获得美国食品药品监督管理局 (“FDA”) 批准试验用新药 (“IND”) 的申请，可启动 SACT-1 的临床试验。 SACT-1...
View ArticleClik here to view.
IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global...
PLEASANTON, Calif. & NANJING, China & SHANGHAI IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative...
View ArticleClik here to view.
DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the first patient was dosed in DESTINY-Gastric06, a...
View ArticleClik here to view.
Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by...
WATERTOWN, Mass. Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as...
View ArticleClik here to view.
DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with...
TOKYO & MUNICH & BASKING RIDGE, N.J. New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi...
View ArticleClik here to view.
Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to...
REYKJAVIK, Iceland Alvotech today welcomed the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotech‘s...
View ArticleClik here to view.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the...
BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
View ArticleClik here to view.
武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（简称“武田”）今天宣布，美国食品药品管理局(FDA)已核准EXKIVITY...
View ArticleClik here to view.
ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. Detailed results from the positive DESTINY-Gastric02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan), the Daiichi Sankyo Company, Limited...
View ArticleClik here to view.
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus...
TOKYO & MUNICH & BASKING RIDGE, N.J. Detailed positive results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan), the Daiichi Sankyo Company,...
View ArticleClik here to view.
武田薬品のEXKIVITY™（モボセルチニブ）がEGFRエクソン20挿入変異陽性NSCLC患者向けに特別設計した初の経口治療薬として米国FDAの承認を取得
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） —...
View ArticleClik here to view.
AnHeart Therapeutics Announces Formation of Scientific Advisory Board
NEW YORK & HANGZHOU, China AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today the formation of...
View ArticleClik here to view.
Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer...
TORONTO & SHANGHAI Cyclica, the partner of choice for data-driven drug discovery, and IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted...
View ArticleClik here to view.
AbCellera and Everest Medicines Announce Multi-Target Collaboration to...
VANCOUVER, British Columbia & SHANGHAI AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, “Everest”) announced today that they have entered into a multi-year collaboration and...
View ArticleClik here to view.
Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3...
PLEASANTON, Calif. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announced updated clinical data, including median overall...
View ArticleClik here to view.
Rhizen PharmaceuticalsがCovid-19患者でRP7214を検討する第2相試験で最初の患者への投与を発表
スイス・バーゼル （ビジネスワイヤ） — オンコロジー・炎症分野に傾注する臨床段階のバイオ製薬企業であるRhizen Pharmaceuticals...
View Article